Avalor Health Care Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Avalor Health Care Private Limited Pharmaceutical Export Portfolio Dataset — 5 Products, $769.1K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Avalor Health Care Private Limited — Pharmaceutical Exporter Profile (2026) | 5 Products, $769.1K Trade | TransData Nexus

Avalor Health Care Private Limited

Indian Pharmaceutical Exporter · Tuberculosis Medications Specialist · $769.1K Total Trade · DGFT Verified

Avalor Health Care Private Limited is an Indian pharmaceutical exporter with a total trade value of $769.1K across 5 products in 3 therapeutic categories. Based on 38 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Fluticasone ($300.0K), Isoniazid ($227.2K), Ethambutol ($113.6K).

Avalor Health Care Private Limited — Export Portfolio & Destination Treemap

Avalor Health Care Private Limited pharmaceutical export portfolio — 5 products across 3 therapeutic categories. Source: Indian Customs (DGFT).

Who is Avalor Health Care Private Limited? — Company Overview & Market Position

Avalor Health Care Private Limited is an Indian pharmaceutical exporter established on September 23, 2008. The company is registered under the Corporate Identification Number (CIN) U15490UP2008PTC162042, with its registered office located at B-949, iThum Tower, Plot No. A 40, Sector 62, Noida, Uttar Pradesh, 201301.

The company is privately held, with authorized and paid-up capital of ₹100,000 each. As of the latest available data, the directors are Archana Singh and Minu Singh.

In the fiscal year ending March 31, 2025, Avalor Health Care reported a significant growth in revenue, with a 102.95% increase compared to the previous year. The company's net worth also saw a substantial rise of 40.07%.

What Does Avalor Health Care Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Fluticasone$300.0K 2Isoniazid

Product Portfolio — Top 5 by Export Value

Avalor Health Care Private Limited exports 5 pharmaceutical products across 3 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Fluticasone	Respiratory	$300.0K	6	0.1%	10
2	Isoniazid	Tuberculosis Medications	$227.2K	12	0.0%	15
3	Ethambutol	Tuberculosis Medications	$113.6K	6	0.0%	14
4	Pyrazinamide	Tuberculosis Medications	$113.6K	6	0.0%	14
5	Thalidomide	Advanced Oncology	$14.7K	8	0.8%	14

Avalor Health Care Private Limited exports 5 pharmaceutical products across 3 therapeutic categories with a total export value of $769.1K. The top category is Tuberculosis Medications (59.1% of portfolio), followed by Respiratory (39.0%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Avalor Health Care Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

The company is privately held, with authorized and paid-up capital of ₹100,000 each. As of the latest available data, the directors are Archana Singh and Minu Singh.

2Manufacturing Facilities

Avalor Health Care Private Limited operates manufacturing facilities in Noida, Uttar Pradesh, India. The company specializes in the production of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Specific details regarding the capacities and certifications of these facilities are not publicly disclosed.

3Key Leadership

The leadership team of Avalor Health Care Private Limited comprises:

Archana Singh: Director since September 23, 2008.

Minu Singh: Director since April 30, 2018.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Avalor Health Care Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Avalor Health Care Private Limited's presence in regulated markets such as the United States, European Union, United Kingdom, Australia, and Japan is not publicly documented. The company primarily exports finished pharmaceutical formulations, but specific regulatory filings, approvals, and market access statuses in these regions are not available in the provided data.

2Emerging Markets

The company's export data indicates a focus on tuberculosis medications, respiratory drugs, and advanced oncology treatments. However, specific information regarding market penetration in Africa, Latin America, and Southeast Asia, as well as WHO prequalification status, is not available in the provided data.

3Geographic Strategy

Avalor Health Care Private Limited's export portfolio is concentrated in five products across three therapeutic categories, with tuberculosis medications comprising 59.1% of exports. This concentration suggests a strategic focus on specific therapeutic areas, which may present both opportunities and risks. Diversification into additional therapeutic categories and geographic regions could mitigate potential market fluctuations.

Avalor Health Care Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific information regarding Avalor Health Care Private Limited's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history is not publicly available. The company's export data does not provide insights into its standing with the U.S. Food and Drug Administration.

2WHO & EU GMP

There is no publicly available information regarding Avalor Health Care Private Limited's compliance with World Health Organization (WHO) prequalification, European Union Good Manufacturing Practice (EU GMP) certificates, or European Directorate for the Quality of Medicines & HealthCare (EDQM) status. The company's export data does not indicate adherence to these international quality standards.

3CDSCO & Indian Regulatory

Specific details about Avalor Health Care Private Limited's compliance with the Central Drugs Standard Control Organisation (CDSCO) manufacturing licenses, state drug controller approvals, and export No Objection Certificates (NOCs) are not publicly disclosed. The company's export data does not provide insights into its regulatory standing within India.

Avalor Health Care Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Avalor Health Care Private Limited operates in the pharmaceutical export sector, focusing on finished formulations in tuberculosis medications, respiratory drugs, and advanced oncology treatments. While specific competitors are not identified in the provided data, the company faces competition from other Indian pharmaceutical exporters with diverse product portfolios and established international market presence. Avalor's concentration in specific therapeutic areas may limit its competitiveness compared to more diversified competitors.

2Key Differentiators

Avalor Health Care Private Limited's key differentiators include its specialization in tuberculosis medications, respiratory drugs, and advanced oncology treatments. The company's focus on finished pharmaceutical formulations allows for direct market entry without the complexities associated with active pharmaceutical ingredient (API) production. However, the lack of diversification in its product portfolio may limit its ability to adapt to changing market demands.

3Strategic Position

Avalor Health Care Private Limited's current strategic direction appears to be focused on the export of finished pharmaceutical formulations in specific therapeutic areas. The company's future outlook would benefit from diversification into additional therapeutic categories and geographic regions to mitigate risks associated with market concentration and to capitalize on emerging global health trends.

Buyer Due Diligence Brief — Evaluating Avalor Health Care Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Avalor Health Care Private Limited's export data indicates a total export value of $769,000 USD across 38 shipments, with a portfolio concentration of 100% in its top five products. This suggests a consistent export volume, albeit with a narrow product focus. The company's reliability as a supplier may be influenced by its limited product diversification and potential exposure to market fluctuations in its specialized therapeutic areas.

2Certifications to Verify

Importers should verify the following certifications to ensure product quality and regulatory compliance:

FDA Approval: Confirm that the company's products are approved by the U.S. Food and Drug Administration. Verification can be done through the FDA's official website or by contacting the company directly.

WHO-GMP Certification: Ensure that the manufacturing facilities comply with World Health Organization Good Manufacturing Practice standards. This can be verified by reviewing the company's certifications or contacting the World Health Organization.

Frequently Asked Questions — Avalor Health Care Private Limited

How many pharmaceutical products does Avalor Health Care Private Limited export from India?

Avalor Health Care Private Limited exports 5 pharmaceutical products across 3 therapeutic categories. The top exports are Fluticasone ($300.0K), Isoniazid ($227.2K), Ethambutol ($113.6K), Pyrazinamide ($113.6K), Thalidomide ($14.7K). Total export value is $769.1K.

What is Avalor Health Care Private Limited's total pharmaceutical export value?

Avalor Health Care Private Limited's total pharmaceutical export value is $769.1K, based on 38 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Avalor Health Care Private Limited cover?

Avalor Health Care Private Limited exports across 3 therapeutic categories. The largest are Tuberculosis Medications (59.1%, 3 products), Respiratory (39.0%, 1 products), Advanced Oncology (1.9%, 1 products).

Get Full Avalor Health Care Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.